Cingulate Inc. Files S-1/A for Potential Stock Offerings

TL;DR

Cingulate Inc. filed an S-1/A, looks like they're prepping for a stock sale. Keep an eye on this.

AI Summary

Cingulate Inc. filed an S-1/A on October 3, 2024, to register an indeterminate amount of securities for sale. The company, based in Kansas City, KS, is in the pharmaceutical preparations industry and is incorporated in Delaware. This filing indicates potential future stock offerings.

Why It Matters

This S-1/A filing by Cingulate Inc. signals their intention to potentially offer more shares to the public, which could impact the stock's supply and demand dynamics.

Risk Assessment

Risk Level: medium — S-1/A filings often precede stock offerings, which can dilute existing shares and introduce market volatility.

Key Numbers

• 333-282358 — SEC File Number (Identifies this specific registration statement)
• 0001862150 — Central Index Key (Unique identifier for Cingulate Inc. in SEC filings)

Key Players & Entities

• Cingulate Inc. (company) — Registrant
• October 3, 2024 (date) — Filing Date
• Kansas City, KS (location) — Company Address
• Delaware (location) — State of Incorporation
• Shane J. Schaffer (person) — Chief Executive Officer
• Michael J. Lerner, Esq. (person) — Legal Counsel
• Steven M. Skolnick, Esq. (person) — Legal Counsel
• Lowenstein Sandler LLP (company) — Legal Firm

FAQ

Key Financial Figures

• $0.0001 — ne share of its common stock, par value $0.0001 per share, to Cingulate Therapeutics, L
• $0.024 — are, to Cingulate Therapeutics, LLC for $0.024. Such issuance was exempt from registra
• $5 million — 22, Cingulate Therapeutics LLC issued a $5 million promissory note (the “August Note
• $8.0 million — ote to increase the principal amount to $8.0 million (as so amended and restated, the &ldquo
• $12.0 million — the right to sell to Lincoln Park up to $12.0 million in shares of common stock, subject to c
• $131 — stock at a purchase price per share of $131.64, for aggregate gross proceeds to the
• $1.0 m — roceeds to the Company of approximately $1.0 million, before deducting transaction exp
• $5,000,000 — ant to which WFIA agreed to convert the $5,000,000 under the Amended and Restated Note plu
• $5,812,500 — e plus all accrued interest thereon, or $5,812,500, into pre-funded warrants (“WIFA
• $204.00 — version price per Pre-Funded Warrant of $204.00. The Pre-Funded Warrants have no expira
• $0 — ble immediately at an exercise price of $0..024 per share. Such issuance was exemp
• $3.0 million — ch WFIA agreed to convert the remaining $3.0 million of principal under the WFIA Note plus a
• $3,287,500 — e plus all accrued interest thereon, or $3,287,500, into pre-funded warrants (the “J
• $52.20 — stock on Nasdaq on January 24, 2024 was $52.20 per share. The January WFIA Pre-Funded
• $0.0012 — ble immediately at an exercise price of $0.0012 per share, to the extent that after giv

Filing Documents

• forms-1a.htm (S-1/A) — 186KB
• ex23-1.htm (EX-23.1) — 3KB
• 0001493152-24-039276.txt ( ) — 190KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Kansas City, Kansas, on the day of October 3, 2024. CINGULATE INC. By: /s/ Shane J. Schaffer Name: Shane J. Schaffer Title: Chief Executive Officer Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities held on the dates indicated: Signature Title Date /s/ Shane J. Schaffer Shane J. Schaffer Chief Executive Officer, Chairman (Principal Executive Officer) October 3, 2024 /s/ Jennifer L. Callahan Jennifer L. Callahan Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) October 3, 2024 * October 3, 2024 Peter J. Werth Director * October 3, 2024 Bryan Lawrence Director * October 3, 2024 Jeffrey Ervin Director * October 3, 2024 John Roberts Director *By: /s/ Shane J. Schaffer Shane J. Schaffer Attorney-in-Fact I

View Full Filing

View this S-1/A filing on SEC EDGAR